# A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Source: https://onco.cc/trials/nct06782555/  
OnCo record `nct06782555` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Zalifrelimab and Balstilimab in prostate cancer, head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma, run by ImmunoGenesis, now recruiting.

## Summary

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab is a phase 1/2 interventional study registered as NCT06782555 by ImmunoGenesis, with 71 participants planned, started 2025-01-08 and due to reach its primary completion in 2027-10. Interventions recorded: Evofosfamide, Zalifrelimab and Balstilimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06782555
- Phase: 1/2
- Setting: A Phase 1/2 Immunotherapy Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab in Patients with Advanced Solid Malignancies
- Sponsor: ImmunoGenesis
- Enrolled: 71

## Sources

- ClinicalTrials.gov NCT06782555: https://clinicaltrials.gov/study/NCT06782555

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Balstilimab](https://onco.cc/drugs/balstilimab/), [Zalifrelimab](https://onco.cc/drugs/zalifrelimab/)
- companies: [Agenus](https://onco.cc/companies/agenus/)

---
JSON: https://onco.cc/api/v1/entities/nct06782555.json